Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 629

1.

Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.

Rosengart TK, Romeiser JL, White LJ, Fratello A, Fallon E, Senzel L, Shroyer AL.

J Thorac Cardiovasc Surg. 2013 Nov;146(5):1259-1266, 1266.e1; discussion 1266. doi: 10.1016/j.jtcvs.2013.06.029. Epub 2013 Aug 13.

2.

Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study.

Reed GW, Kumar A, Guo J, Aranki S, Shekar P, Agnihotri A, Maree AO, McLean DS, Rosenfield K, Cannon CP.

Clin Cardiol. 2015 Feb;38(2):92-8. doi: 10.1002/clc.22357. Epub 2015 Feb 5.

3.

A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.

Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G.

JACC Cardiovasc Interv. 2012 Mar;5(3):281-9. doi: 10.1016/j.jcin.2012.01.009.

4.

Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).

Kirtane AJ, Parikh PB, Stuckey TD, Xu K, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Mazzaferri EL Jr, Parvataneni R, Maehara A, Généreux P, Mehran R, Stone GW.

JACC Cardiovasc Interv. 2015 Dec 28;8(15):1978-87. doi: 10.1016/j.jcin.2015.08.032.

5.

Impact of initial clinical presentation on clopidogrel low response.

Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM, Lemesle G.

Arch Cardiovasc Dis. 2013 Nov;106(11):593-600. doi: 10.1016/j.acvd.2013.06.050. Epub 2013 Sep 23.

6.

Switching acute coronary syndrome patients from prasugrel to clopidogrel.

Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G.

JACC Cardiovasc Interv. 2013 Feb;6(2):158-65. doi: 10.1016/j.jcin.2012.09.012.

7.
8.

The effect of acenocoumarol on the antiplatelet effect of clopidogrel.

Dewilde WJ, Janssen PW, Bergmeijer TO, Kelder JC, Hackeng CM, ten Berg JM.

Thromb Haemost. 2015 Oct;114(4):708-16. doi: 10.1160/TH15-02-0130. Epub 2015 Jul 16.

PMID:
26177793
9.

Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.

Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS.

Cardiovasc Ther. 2012 Feb;30(1):5-11. doi: 10.1111/j.1755-5922.2010.00249.x. Epub 2010 Dec 6.

PMID:
21129165
10.

Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.

Reed GW, Cannon CP, Waalen J, Teirstein PS, Tanguay JF, Berger PB, Angiolillo DJ, Price MJ.

Catheter Cardiovasc Interv. 2017 Feb 1;89(2):190-198. doi: 10.1002/ccd.26428. Epub 2016 Feb 23.

PMID:
26909669
11.

The STIB score: a simple clinical test to predict clopidogrel resistance.

Legrand D, Barbato E, Chenu P, Magne J, Vrolix M, Wijns W, Legrand V; STIB investigators.

Acta Cardiol. 2015 Oct;70(5):516-21. doi: 10.2143/AC.70.5.3110511.

PMID:
26567810
12.
13.

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.

Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD.

Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1.

14.

A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.

Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D.

Thromb Haemost. 2014 Aug;112(2):342-51. doi: 10.1160/TH13-10-0874. Epub 2014 Apr 10.

PMID:
24718389
16.

Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery.

Herman CR, Buth KJ, Kent BA, Hirsch GM.

Ann Thorac Surg. 2010 Feb;89(2):397-402. doi: 10.1016/j.athoracsur.2009.10.051.

PMID:
20103308
17.

Effect of clopidogrel on bleeding after coronary artery bypass surgery.

Yende S, Wunderink RG.

Crit Care Med. 2001 Dec;29(12):2271-5.

PMID:
11801823
18.

Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study.

Kremke M, Tang M, Bak M, Kristensen KL, Hindsholm K, Andreasen JJ, Hjortdal V, Jakobsen CJ.

Eur J Cardiothorac Surg. 2013 Aug;44(2):e133-40. doi: 10.1093/ejcts/ezt230. Epub 2013 May 9.

PMID:
23660554
19.

CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel.

Park JJ, Park KW, Kang J, Jeon KH, Kang SH, Ahn HS, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS.

Circ J. 2013;77(5):1289-96. Epub 2013 Feb 9.

20.

Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.

Yang TH, Kim DI, Kim DK, Jang JS, Kim U, Seol SH, Kim DK, Hong GR, Park JS, Shin DG, Kim YJ, Cho YK, Nam CW, Hur SH, Kim KB, Kim DS.

Korean J Intern Med. 2011 Jun;26(2):145-52. doi: 10.3904/kjim.2011.26.2.145. Epub 2011 Jun 1.

Supplemental Content

Support Center